One approved targeted therapy, no advancing rival, and a cost-effectiveness case that argues against it. Defending this franchise is a different problem from winning a contested one.
Cold agglutinin disease is effectively a single-agent market. One targeted therapy is approved, and the next-generation pipeline stalled when two credible challengers were discontinued in the indication. That removes the usual competitive questions and replaces them with a harder one: how to defend price and access when the challenge comes from the payer rather than from a rival.
The value problem is stark. Published cost-effectiveness sits far above any conventional threshold, and a peer-reviewed US analysis found standard of care favoured in every iteration, implying a very large price reduction to reach conventional value. A franchise in that position cannot argue on cost-effectiveness terms and has to build the case on unmet need, on the absence of an alternative, and on outcomes that a QALY framework captures poorly.
Sizing has to separate a positive laboratory finding from a treatable patient. Many people with detectable cold agglutinins are asymptomatic, or carry transient infection-driven titres that resolve. A positive test alone overstates the market substantially. The commercial population is the subset who haemolyse clinically and are symptomatic enough to treat, and isolating that group is the first analytical task in any cold agglutinin disease model.
AXLRx cold agglutinin disease reports isolate the treatable population from the test-positive one, and build the defence of a single-agent franchise against its own value case.
Cold agglutinin disease is a rare classical-complement autoimmune haemolytic anaemia driven by cold-reactive IgM. This separates primary CAD from cold agglutinin syndrome and sizes the US haemolysis burden.
Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
Sutimlimab's CARDINAL trial left 46% of patients without a haemoglobin response. The two most-advanced next-generation complement inhibitors then abandoned cold agglutinin disease after its launch, leaving the entry gap defined by non-response and cost, not a clinical rival.
US cold agglutinin disease sizing starts from a rate range, not a point estimate. Incidence 0.6-1.2 and 1-year prevalence 1.4-3.1 per 100,000 imply ~5,000 prevalent patients. No published treated-share figure exists to split served from total addressable.
Sutimlimab costs $259,000-$302,000 per patient per year. A peer-reviewed analysis puts its ICER at $2.34M/QALY, with standard of care favoured in all 10,000 probabilistic-sensitivity iterations. The value gap, not a rival drug, sets the pricing discipline.
Cold agglutinin disease is an ultra-rare autoimmune hemolytic anemia driven by cold-reactive IgM antibodies. A US claims analysis put incidence at 0.6 to 1.2 per 100,000 person-years and 1-year prevalence at 1.4 to 3.1 per 100,000 adults, implying an order-of-magnitude pool of roughly 5,000 US patients. The population is female-predominant with a median age near 71, and incidence rises with age. Primary CAD reflects a clonal low-grade B-cell lymphoproliferative disorder, distinct from secondary cold agglutinin syndrome.
Diagnosis turns on separating CAD from warm autoimmune hemolytic anemia and from secondary cold agglutinin syndrome. The direct antiglobulin test is positive for complement C3d, an elevated cold agglutinin titer is confirmed, and thermal-amplitude testing establishes antibody reactivity near body temperature. LDH and bilirubin anchor the hemolysis workup. Primary CAD reflects a clonal B-cell disorder producing monoclonal cold-reactive IgM. Diagnostic delay and misclassification as other anemias remain common before the cold-reactive mechanism is confirmed.
One therapy is FDA-approved: sutimlimab (Enjaymo), an intravenous humanized anti-C1s classical-complement inhibitor approved February 4, 2022. It is marketed by Recordati Rare Diseases, having originated at Sanofi, and is dosed by body weight every two weeks. In the CARDINAL trial, 54% of patients met the composite hemoglobin-response endpoint, mean hemoglobin rose 2.6 g/dL, and 71% stayed transfusion-free from week 5 to 26. The CADENZA trial confirmed benefit in transfusion-naive patients. Sutimlimab competes against off-label rituximab regimens and cold avoidance, not a branded rival.
Published CAD prevalence spans 1.4 to 3.1 per 100,000, and the roughly 5,000-patient US pool is an order-of-magnitude estimate rather than a census. When epidemiology is this thin, we triangulate the addressable pool off disease burden rather than counts. We anchor to the transfusion-dependent and symptomatic-hemolysis segments, using elevated LDH, low hemoglobin, and transfusion or cold-avoidance history that persist in claims even where CAD itself is miscoded. AXLRx's Market Sizing Model then builds a bottom-up TAM from that burden-defined pool, multiplied by sutimlimab's $259,000 to $302,000 annual cost, and flags treated-share as an explicit gap rather than inventing a penetration figure. Burden, not headcount, sizes the market.
Many people with detectable cold agglutinins are asymptomatic or carry transient, infection-driven titers, so a positive test alone overstates the market. The commercial question is which patients hemolyze enough to warrant a therapy priced above $259,000 per year. We build a diagnosis-refinement funnel that narrows from all cold-agglutinin-positive results down through DAT positivity for C3d, thermal-amplitude confirmation, and evidence of active hemolysis to the symptomatic, primary-CAD subset sutimlimab is designed to treat. Each narrowing step is a patient-finding intervention that separates primary CAD from secondary cold agglutinin syndrome and from warm autoimmune hemolytic anemia. Quantifying that funnel, not the raw seropositive count, is what defines addressable volume.
CAD is a single-agent market: sutimlimab is the only FDA-approved targeted therapy, and the next-generation pipeline stalled when pegcetacoplan (Apellis and Sobi) and iptacopan (Novartis) discontinued CAD-specific programs as the eligible pool thinned, leaving riliprubart (Sanofi) at only Phase 1b. Forecasting here is not a share-of-voice race against a branded competitor, so we model against the real alternatives, off-label rituximab regimens and cold avoidance, and against sutimlimab's own 46% composite non-response rate. Defense rests on identification economics and durability, since hemolysis recurs when C1s inhibition stops. AXLRx's Competitive Intelligence and Launch Readiness reports frame the opening as one defined by the incumbent's gaps, not an oncoming threat.
Sutimlimab carries an ICER of $2.34 million per QALY against a $150,000 threshold, and a peer-reviewed US analysis found standard of care favored in every iteration, implying roughly an 80% price reduction to meet conventional value benchmarks. A defensible value case therefore cannot rest on QALYs alone. We build it on transfusion-avoidance and hemolysis control, translating the 71% of CARDINAL patients staying transfusion-free and the mean 2.6 g/dL hemoglobin gain into avoided transfusion costs, reduced fatigue and thrombosis risk, and Part B budget-impact math across a roughly 5,000-patient pool. AXLRx's Pricing Strategy Model and Payer & HTA reports position the argument around burden offset rather than cost-per-QALY, where the drug cannot win.
Every answer here draws on AXLRx's US cold agglutinin disease report set: Disease Landscape, Market Sizing Model, Competitive Intelligence, Launch Readiness, Pricing Strategy Model, and Payer & HTA, each built from source-verified epidemiology, trial data, and pricing evidence. The connecting thesis is that in CAD the identification and burden funnel is the strategy: value is won by finding the symptomatic, transfusion-dependent patient and quantifying that pool, not by out-shouting a rival that does not exist. Coverage today is US-focused; UK and GCC questions extend the same report types into each market's HTA, access, and channel structure.